Active Ingredient(s): Maralixibat Chloride
FDA Approved: * September 29, 2021
Pharm Company: * MIRUM
Category: Genetic Disorders

Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome.[1] Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.[1] Maralixibat was approved for medical use in the United States in September 2021.[1][2][3] Contents 1 History 2 Names 3 References 4 External links History Maralixibat was granted orphan dr... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Livmarli 9.5 mg/ml Oral Solution
NDC: 79378-110
Mirum Pharmaceuticals Inc.